SCHEDULE 13G/A: BlackRock Discloses 1.9% Passive Stake in Ovid Therapeutics
Beneficial Ownership Report
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 1.9% passive beneficial ownership stake in Ovid Therapeutics Inc. as of June 30, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 1,369,010 shares of Ovid Therapeutics Inc. common stock.
- This ownership represents 1.9% of the total outstanding common stock of Ovid Therapeutics Inc.
- BlackRock holds sole voting power over 1,359,560 shares and sole dispositive power over 1,369,010 shares.
- The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
- BlackRock, Inc. is a Delaware corporation with its principal business office at 50 Hudson Yards, New York, NY 10001.
- Ovid Therapeutics Inc.'s principal executive offices are located at 441 Ninth Avenue, 14th Floor, New York, NY 10001.
Sentiment
Score: 5
Explanation: The document is a routine compliance filing disclosing a passive ownership stake, providing no direct positive or negative operational news about the issuer. The sentiment is neutral.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
NA
Management Comments
- The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.
Industry Context
NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Internal Authorization Update | BlackRock, Inc. updated its Power of Attorney, revoking a previous one dated April 30, 2023, and appointing new attorneys-in-fact effective January 21, 2025, for compliance with ownership reporting requirements. | 2025-01-21 | This is an internal governance update for BlackRock, Inc. to streamline its SEC filing processes and does not directly impact Ovid Therapeutics Inc.'s corporate governance. |
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's passive stake, which may offer some confidence but does not imply active involvement in company strategy.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous Power of Attorney revoked by BlackRock, Inc. |
| 2025-01-21 | Effective date of the new Power of Attorney for BlackRock, Inc. |
| 2025-06-30 | Date of event which requires filing of this statement (reporting period end date). |
| 2025-07-17 | Date of filing of this Schedule 13G Amendment No. 1. |
Keywords
BlackRock, Ovid Therapeutics Inc., Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.